DIAGNOS and ETS to Present Ground-breaking Research on Mass Screening for Macular Edema at ARVO 2023
February 14 2023 - 9:36AM
Diagnos Inc. (“DIAGNOS”, the “Corporation” or ”we”) (TSX Venture:
ADK) (OTCQB: DGNOF) is a leader in early detection of critical
health issues through the use of its FLAIRE platform based on
Artificial Intelligence (AI). DIAGNOS and École de Technologie
Supérieure (ÉTS), a world-renowned technical university, are proud
to announce that they will be presenting the results of their
ground-breaking research on mass screening for macular edema using
Optical Coherence Tomography (OCT) at ARVO 2023, the Annual
Conference of the Association for Research in Vision and
Ophthalmology (ARVO).
The research, which has been selected by the
ARVO imaging program committee, represents a major advancement in
the field of medical imaging and highlights the important work
being carried out by DIAGNOS and ÉTS.
Macular edema is a serious eye condition, it
remains the most common cause of vision loss among diabetics and
AMD patients, and its early detection is crucial for effective
treatment. The screening process for macular edema has been
revolutionized by the research carried out by DIAGNOS and ÉTS,
resulting in impressive efficiency of algorithms, fidelity of the
"heat map" type decision-making tool, and an extremely low rate of
"false positives." This will make the screening process faster,
more accurate, and more accessible to the general population.
DIAGNOS’ AI-enabled screening process is likely
to become the go-to method adopted by healthcare professionals in
the future. The use of AI technology has made it possible to detect
macular edema quickly and accurately, and this will revolutionize
the way healthcare professionals approach mass screening for this
condition. The OCT market is rapidly expanding and DIAGNOS is well
positioned to be successful in this rapidly growing market. With
the company’s commitment to innovation and cutting-edge technology,
DIAGNOS is poised to play a major role in the continued growth and
development of the OCT market.
"We are thrilled to be presenting our research
at ARVO 2023 and to be recognized by the ARVO imaging program
committee as leaders in our field," said Mr. André Larente,
President of DIAGNOS. "Our collaboration with ÉTS has
allowed us to make great strides in the development of efficient
and accurate Deep Learning Algorithms for the screening of macular
edema, and we believe that this work will have a significant impact
on the lives of those affected by this condition. With the OCT
market expanding rapidly, we are confident that DIAGNOS will
continue to be at the forefront of medical imaging innovation."
About ARVOThe Association for Research in Vision
and Ophthalmology (ARVO) is the largest eye and vision research
organization in the world. Members include approximately 10,000 eye
and vision researchers from over 75 countries. ARVO advances
research worldwide into understanding the visual system and
preventing, treating, and curing its disorders. The ARVO annual
conference is a premier event in the field of vision research,
bringing together scientists, clinicians, and industry
professionals from around the world to share their latest findings
and innovations. The conference will take place between April 23rd
and 27th, in New Orleans.
Additional information is available at
www.arvo.org
About ÉTS
École de technologie supérieure is one of ten
constituents of the Université du Québec network. It trains
engineers and researchers who are recognized for their practical
and innovative approach, the development of new technologies and
their skill at transferring their knowledge to companies. Almost
one-quarter of all engineers in Québec graduated from ÉTS, which
boasts 11,000 students, including 2,650 at the graduate and
post-graduate level. ÉTS specializes in applied training and
research in engineering, and maintains a unique partnership with
the business sector and with industry.
Additional information is available at
www.etsmtl.ca
About DIAGNOSDIAGNOS is a publicly traded
Canadian corporation dedicated to early detection of critical
health problems based on its FLAIRE Artificial Intelligence (AI)
platform. FLAIRE allows for quick modifying and developing of
applications such as CARA (Computer Assisted Retina Analysis).
CARA’s image enhancement algorithms provide sharper, clearer and
easier-to-analyze retinal images. CARA is a cost-effective tool for
real-time screening of large volumes of patients. CARA has been
cleared for commercialization by the following regulators: Health
Canada, the FDA (USA) and Saudi FDA (Saudi Arabia).
Additional information is available at
www.diagnos.com and www.sedar.com
For further information, please contact:
Mr. André Larente, PresidentDIAGNOS Inc.Tel: 450
678-8882, ext. 224Email: alarente@diagnos.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/fcb8003e-2b1b-4cd2-a7af-5dffda3d133a
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024